Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Bendamustine with dexamethasone in R/R systemic AL amyloidosis

Raymond Comenzo • 20 Jul 2020
Amyloidosis Rare Diseases Antibodies Bendamustine Daratumumab Dexamethasone Ixazomib Lenalidomide Melphalan Prednisone

Raymond Comenzo MD, of Tufts University School of Medicine, Boston, MA, outlines the use of bendamustine with dexamethasone, as an alternative, well-tolerated therapy in relapsed/refractory (R/R) systemic light-chain (AL) amyloidosis. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).

More from Raymond Comenzo

2:54
Main results from the ANDROMEDA study
Raymond Comenzo • 1 Jun 2020
5:23
Dual antibody therapy in patients with systemic AL amyloidosis and cardiac involvement
Raymond Comenzo • 1 Jun 2020
13:14
Amyloidosis: diagnosis and stem cell transplantation
Morie Gertz et al. • 14 Sep 2019
12:03
How will novel agents affect the amyloidosis population?
Morie Gertz et al. • 14 Sep 2019

Related Videos

0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:59
The common clinical manifestations of BPDCN
Anthony Stein • 15 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals